Drugs

Photo taken from Carl Ola Landgren/Twitter

Apr 26, 2024, 14:15

Carl Ola Landgren: With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients access to new therapies will be much quicker

Carl Ola Landgren, Chief of the Myeloma Division and Translational Clinical Oncology Program at Sylvester Comprehensive Cancer Center, shared a post on X/Twitter:

“With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients’ access to new therapies will be much quicker.

Instead of waiting for 10-15 years, new drugs can be available in 3-5 years. Here is how it works.”

Source: Carl Ola Landgren/X

cancer Carl Ola Landgren MRD multiple myeloma Myeloma OncoDaily Oncology Sylvester Comprehensive Cancer Center Translational Clinical Oncology With Minimal Residual Disease

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC